Biomics Biopharma (ASX:BBM) Loans Receivable: A$0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biomics Biopharma Loans Receivable?

Biomics Biopharma ASX:BBM Loans Receivable is A$0.00 Mil as of . 20.

Biomics Biopharma's Loans Receivable for the quarter that ended in . 20 was A$0.00 Mil.

Biomics Biopharma Loans Receivable Related Terms

Biomics Biopharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Loans Receivable Chart

Biomics Biopharma Annual Data
Trend
Loans Receivable

Biomics Biopharma Semi-Annual Data
Loans Receivable

Biomics Biopharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of A$0.00 Mil mean?
Biomics Biopharma (ASX:BBM) has a Loans Receivable of A$0.00 Mil as of . 20. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Loans Receivable too high?
Biomics Biopharma's current Loans Receivable is A$0.00 Mil.
How does Biomics Biopharma's Loans Receivable compare to competitors?
Biomics Biopharma's Loans Receivable of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current Loans Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Loans Receivable of A$0.00 Mil. The current Loans Receivable is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Loans Receivable is A$0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.